Review
doi: 10.1200/JCO.2006.06.8080.
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker
Affiliations
- PMID: 16829653
- DOI: 10.1200/JCO.2006.06.8080
Item in Clipboard
Review
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker
J Clin Oncol.
.
Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is being used in oncology as a noninvasive method for measuring properties of the tumor microvasculature. There is potential for DCE-MRI to be used as an imaging biomarker to measure antiangiogenic effects of cancer treatments. This article reviews the general methodology for performing DCE-MRI and discusses existing data and challenges to applying DCE-MRI for treatment response assessment in clinical trials.
Similar articles
-
Molecular imaging of antiangiogenic agents.Oncologist. 2005 Feb;10(2):92-103. doi: 10.1634/theoncologist.10-2-92. Oncologist. 2005. PMID: 15709211 Review.
-
Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.J Magn Reson Imaging. 2002 Oct;16(4):407-22. doi: 10.1002/jmri.10176. J Magn Reson Imaging. 2002. PMID: 12353256 Review.
-
Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging.Abdom Imaging. 2005 May-Jun;30(3):324-41. doi: 10.1007/s00261-004-0265-5. Abdom Imaging. 2005. PMID: 15688112 Review.
-
Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies.Clin Radiol. 2001 Aug;56(8):607-20. doi: 10.1053/crad.2001.0762. Clin Radiol. 2001. PMID: 11467863 Review.
-
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.Magn Reson Imaging. 2007 Apr;25(3):319-27. doi: 10.1016/j.mri.2006.09.041. Epub 2007 Feb 5. Magn Reson Imaging. 2007. PMID: 17371720
Cited by
-
Unbalanced regularized optimal mass transport with applications to fluid flows in the brain.Sci Rep. 2024 Jan 11;14(1):1111. doi: 10.1038/s41598-023-50874-y. Sci Rep. 2024. PMID: 38212659 Free PMC article.
-
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.BMC Cancer. 2016 Jul 13;16:466. doi: 10.1186/s12885-016-2494-8. BMC Cancer. 2016. PMID: 27412562 Free PMC article. Clinical Trial.
-
Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.Contrast Media Mol Imaging. 2018 Sep 19;2018:3181258. doi: 10.1155/2018/3181258. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 30327584 Free PMC article. Clinical Trial.
-
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0. Clin Pharmacokinet. 2019. PMID: 31016670 Free PMC article. Review.
-
Kinetic Features of Invasive Breast Cancers on Computer-Aided Diagnosis Using 3T MRI Data: Correlation with Clinical and Pathologic Prognostic Factors.Korean J Radiol. 2019 Mar;20(3):411-421. doi: 10.3348/kjr.2018.0587. Korean J Radiol. 2019. PMID: 30799572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
